Jon Hu

Co-founder and CEO @pepper_bio | Biotech nerd
@HarvardHBS MBA | @NorthwesternU Undergrad
Former @BainAlerts, @TakedaPharma (Shire Pharma)

[Jon Hu @Jonyuhu]

Shared my thoughts on 2024's pharma trends with @PharmaVoice's @MeaganParrish. Despite the challenges ahead there are big opportunities too. More on how March-In rights might impact biotech, and other trends from industry leaders here: https://t.co/rL5FGgR356

[Pepper Bio @pepper_bio]

At #JPM2024, our CEO @jonyuhu shared with @PharmaVoice's @MeaganParrish his perspective on what policies will shape biotech in 2024. '"It's not the first time we've heard of march-in rights, but [they] are more mainstream now,' he says. More here: https://t.co/RqNY7OHGkD

[Jon Hu @Jonyuhu]

@PepperBio is featured in @TechCrunch’s Pitch Deck Teardown! @Haje's insights on our $6.5M seed pitch stress the value of personal connections in biotech – a reminder to tailor messages effectively when merging science and storytelling https://t.co/jMnnikDaNr

[Jon Hu @Jonyuhu]

Join us in giving a warm welcome to Dr. Martin Alexander Gershon, @endeavorfunds, who is starting his role as our senior strategic advisor. Read about his role with @pepper_bio here: https://t.co/SDdxRn6eOC
#transomics  #drugdiscovery

[Jon Hu @Jonyuhu]

How are startups already using AI to transform the way we approach drug discovery? More on this in @WSJ via my conversation with @BrianPGormley and @SamanthaDStrass.
https://t.co/dqQgz7vLpR

[Jon Hu @Jonyuhu]

My op-ed in @statnews explores how patient advocacy groups influence FDA approvals for drugs that don’t have robust clinical data proving impact. Here’s why that's a problem & how I think we can positively redirect patient advocacy for better outcomes: https://t.co/LqSGua3pt2

[Jon Hu @Jonyuhu]

Investors like @Merck + @NFX helped us further understand the need for solutions like Pepper Bio in the pharma space. Samantha & I spoke with @RebeccaTorrenc5 from @BusinessInsider, who covers the pitch deck that led to our seed funding. Check it out here: https://t.co/G93VQGdMbp

[Jon Hu @Jonyuhu]

With our $6.5M seed funding, @PepperBio isn't just advancing drug development; we're accelerating discoveries to put an end to untreatable diseases. Learn more about the funding of our transomics analysis platform via @abracarioca’s latest in @TechCrunch. https://t.co/K96IpXksFb

[Jon Hu @Jonyuhu]

Transomics has the ability to find ways to circumvent drug resistance in diseases like non-small cell lung cancer. Read about our research findings as @Pepper_Bio heads to @AACR in Boston: https://t.co/CcXq5bzWJJ @theNCI @EORTC

[Jon Hu @Jonyuhu]

@JAMANetworkOpen @VPrasadMDMPH @US_FDA @DavidBenjaminMD @mlythoe It'd be interesting to look at cost data. Did 1st-line displacing therapies and 1L alternatives actually create any pricing pressure? If so, how do we realistically increase 1L drugs given logistical challenges in patient recruitment?

[Jon Hu @Jonyuhu]

As a kid who was in ESL when I first immigrated to the USA, it is a childhood dream come true, to contribute to Forbes.

The Root Cause Of Pharma’s Drug Development Problem via @forbes https://t.co/3yb5zfnjdp